Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery (PREOPRAD)
Randomized Phase II/III Study Comparing Preoperative Radiosurgery Versus Postoperative Radiosurgery in Patients With Brain Metastases Eligible for Surgery: Correlation With Histopathological Factors and Radiomic Analysis.
The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.
More specifically, the study seeks to:
- Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
- Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
- Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.
PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.
The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.
調査の概要
状態
詳細な説明
Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Badajoz
-
Badajoz、Badajoz、スペイン、06080
- まだ募集していません
- Hospital Universitario de Badajoz
-
コンタクト:
- Victoria Vera Barragán, MD
- 電話番号:+34924 21 81 00
- メール:victoria.vera@salud-juntaex.es
-
-
Galicia
-
Vigo、Galicia、スペイン、36214
- まだ募集していません
- Hospital do Meixoeiro
-
コンタクト:
- Beatriz Vazquez Barreiro, MD
- 電話番号:+34 986 81 11 11
- メール:Beatriz.vazquez.barreiro@sergas.es
-
-
Madrid
-
Madrid、Madrid、スペイン、28034
- 募集
- Hospital Universitario Ramón y Cajal
-
コンタクト:
- Eva Lizarbe Fernández, MD
- 電話番号:+3491 336 82 22
- メール:eva.lizarbe@gmail.com
-
Madrid、Madrid、スペイン、28034
- まだ募集していません
- Hospital Ruber Internacional
-
コンタクト:
- Rafael Garcia Garcia, MD
- 電話番号:+34913 87 50 00
- メール:rafael.garciag.ce@ruberinternacional.es
-
-
Navarre
-
Pamplona、Navarre、スペイン、31008
- 募集
- Hospital Universitario de Navarra
-
コンタクト:
- Paola Anna Jablonska, MD
- 電話番号:+34848 428 482
- メール:paolajablonska@gmail.com
-
コンタクト:
- Cristina Gutierrez, PhD
- 電話番号:+34848433454
- メール:cristina.gutierrez.povedano@navarra.es
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed solid tumor with one to four brain metastases.
- At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
- Karnofsky Performance Status (KPS) ≥70.
- Life expectancy ≥3 months.
- Ability to undergo MRI examinations.
- Written informed consent provided.
Exclusion Criteria:
- Brain metastases from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
- Prior radiotherapy to the index lesion.
- Leptomeningeal disease at baseline.
- Contraindication to surgery or stereotactic radiosurgery.
- Pregnancy or breastfeeding.
- Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:preoperative radiosurgery
preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
他の名前:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
|
他の:postoperative radiosurgery
standard treatment, consisting of surgical resection followed by irradiation of the tumor bed |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
他の名前:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Locoregional adverse event-free survival
時間枠:From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed. |
From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Meningeal Failure Rate
時間枠:6 and 12 months after randomization.
|
Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI). |
6 and 12 months after randomization.
|
|
Symptomatic Radiation Necrosis Rate
時間枠:6 and 12 months after randomization.
|
Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation. |
6 and 12 months after randomization.
|
|
Local Control Rate
時間枠:6 and 12 months after randomization.
|
Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI. |
6 and 12 months after randomization.
|
|
Distant Brain Failure-Free Survival
時間枠:6 and 12 months after randomization.
|
Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s). |
6 and 12 months after randomization.
|
|
Overall Survival
時間枠:6 and 12 months after randomization.
|
Time from randomization to death from any cause. |
6 and 12 months after randomization.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to Whole-Brain Radiotherapy (WBRT)
時間枠:From randomization until administration of WBRT, up to 42 months.
|
Time from randomization to the administration of whole-brain radiotherapy (WBRT). |
From randomization until administration of WBRT, up to 42 months.
|
|
Health-Related Quality of Life
時間枠:Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden). |
Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
|
Length of Hospital Stay
時間枠:From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge. |
From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
|
Treatment Delay
時間枠:From treatment planning to treatment completion, up to 42 months.
|
Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment. |
From treatment planning to treatment completion, up to 42 months.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。